萊茵生物(002166.SZ):目前工業大麻CBD產品市場價格較年初有一定回升
格隆匯9月13日丨萊茵生物(002166.SZ)近期在接待機構投資者調研時表示,2019年早期階段,由於資本的全面介入,全產業鏈出現暴利現象,各種小工廠如雨後春筍一般冒出來,產能大幅擴張,但隨着時間的推移實際需求增速及政策開放程度並沒有想象中的快,難以支撐上游的快速擴張,最終導致行業在發展初期出現了供需不平衡,價格暴跌。對此,萊茵因為在公司發展過程中也經歷過多個品類價格的大幅變化,有較為充足的應對經驗,因此在建立工業大麻工廠初期已做好較為充分的預判,在成本測算上,已考慮過價格暴跌情況的出現。
公司hemprise正式達到量產階段後,已開展一定量的工業大麻生產,但由於市場價格不理想,未形成較大的對外銷售。目前工業大麻CBD產品市場價格較年初有一定回升,約在260-270美金/kg,就目前的銷售價格情況,如果新一季的原料符合預期,那麼預計毛利仍有30%以上。如果價格進一步恢復至300美金以上,那麼毛利率將進一步提升,因為市場需求擴大以後,我們作為最大的工業大麻提取工廠的規模效應將得到進一步發揮。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.